China NMPA Drug Inspection - Xifeng Minhe Deer Products Processing Co., Ltd. - yam

The Liaoning Provincial Drug Administration, operating under China's National Medical Products Administration (NMPA), issued an announcement on November 28, 2019, detailing the results of a drug quality sampling inspection. This comprehensive inspection, aimed at safeguarding public health, identified 25 batches of drugs from 23 manufacturing companies that failed to comply with established regulations.Primary violations centered on quality deficiencies in numerous Traditional Chinese Medicinal (TCM) herbs and processed pieces, such as Yam from Hebei Yiren Pharmaceutical Co., Ltd., and Lycium bark. Additionally, specific chemical products, including Norfloxacin capsules from Chengdu Jinhua Pharmaceutical Co., Ltd. and Glibenclamide tablets from Tianjin Pacific Pharmaceutical Co., Ltd., were cited for labeling non-compliance. A medical institution preparation, Fuyi Shengjin Tablets, was also deemed non-compliant.Under the regulatory framework of the 'Drug Administration Law of the People's Republic of China,' immediate control measures were implemented. Local drug authorities mandated that the implicated companies cease the sale and use of the non-compliant batches. Furthermore, the administration instructed provincial and municipal departments to initiate investigations and apply penalties to all enterprises and units involved in the production, sale, or use of these substandard drugs, ensuring adherence to quality and safety standards.